The mechanism of widespread reorganization of DNA methylation may be a therapeutic target to prevent or reverse dyskinesia.
A key role for microRNA-155 in brain inflammation and neurodegeneration makes it both a potential therapeutic target and a biomarker for this progressive disorder.
The drug inhibits the activity of a kinase enzyme called LRRK2, and it showed no pathology in rat lungs, kidneys or livers.
Research to identify a new approach to treat Alzheimer’s disease gets new funding after a pilot grant from the Alabama Drug Discovery Alliance.
Erik Roberson, M.D., Ph.D., and Andrew West, Ph.D., have been named co-directors of the Center for Neurodegeneration and Experimental Therapeutics.
UAB expands research into dystonia with a generous gift from the Joel Johnson family.
He has been an active member of the American Parkinson Disease Association Scientific Advisory Board since May 2001 and is the board’s fourth chairman since the organization’s founding in 1961.